Plasma, RBC, leukocyte and platelet content of various PUFAs, lipoxins, resolvins, protectins, maresins, nitrolipids, NO and other eicosanoids such as PGs, LTs, and TXs (thromboxanes) and activities of Δ6 and Δ5 desaturases could be measured both before and after treatment and used as markers to predict future development and prognostic markers of insulin resistance, the metabolic syndrome, atherosclerosis and IHD. This evidence concerns the gene CD59 and atherosclerosis.